Vapotherm, Inc. (NYSE:VAPO) Director Anthony L. Arnerich Purchases 5,000 Shares of Stock

Vapotherm, Inc. (NYSE:VAPOGet Rating) Director Anthony L. Arnerich acquired 5,000 shares of the stock in a transaction on Monday, June 13th. The stock was bought at an average cost of $2.82 per share, with a total value of $14,100.00. Following the completion of the transaction, the director now owns 48,898 shares in the company, valued at $137,892.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

NYSE:VAPO opened at $2.82 on Wednesday. Vapotherm, Inc. has a one year low of $2.71 and a one year high of $31.87. The company has a debt-to-equity ratio of 1.79, a quick ratio of 3.75 and a current ratio of 5.37. The firm has a market cap of $74.91 million, a P/E ratio of -1.02 and a beta of -0.35. The firm has a 50-day simple moving average of $4.40 and a 200-day simple moving average of $12.77.

Vapotherm (NYSE:VAPOGet Rating) last posted its quarterly earnings results on Wednesday, May 4th. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.24). Vapotherm had a negative net margin of 70.49% and a negative return on equity of 97.73%. The business had revenue of $21.62 million during the quarter, compared to the consensus estimate of $21.03 million. During the same quarter in the prior year, the firm posted ($0.40) EPS. The company’s revenue for the quarter was down 33.1% compared to the same quarter last year. On average, research analysts predict that Vapotherm, Inc. will post -3.07 EPS for the current fiscal year.

Several equities research analysts have issued reports on VAPO shares. Piper Sandler lowered their price objective on shares of Vapotherm from $5.00 to $2.50 and set an “underweight” rating for the company in a research report on Thursday, May 26th. Canaccord Genuity Group cut shares of Vapotherm from a “buy” rating to a “hold” rating and lowered their price objective for the company from $12.00 to $5.00 in a research report on Friday, May 6th. BTIG Research lowered their price objective on shares of Vapotherm from $37.00 to $10.00 in a research report on Monday, April 18th. Finally, Canaccord Genuity Group lowered shares of Vapotherm from a “buy” rating to a “hold” rating and reduced their price target for the company from $12.00 to $5.00 in a report on Friday, May 6th.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Dark Forest Capital Management LP bought a new position in shares of Vapotherm during the 3rd quarter worth approximately $48,000. Macquarie Group Ltd. raised its stake in shares of Vapotherm by 211.6% during the 3rd quarter. Macquarie Group Ltd. now owns 2,315 shares of the company’s stock worth $52,000 after acquiring an additional 1,572 shares in the last quarter. BNP Paribas Arbitrage SA raised its stake in shares of Vapotherm by 362.2% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 4,160 shares of the company’s stock worth $93,000 after acquiring an additional 3,260 shares in the last quarter. Royal Bank of Canada raised its stake in shares of Vapotherm by 40.0% during the 2nd quarter. Royal Bank of Canada now owns 4,332 shares of the company’s stock worth $103,000 after acquiring an additional 1,237 shares in the last quarter. Finally, Advisor Group Holdings Inc. raised its stake in shares of Vapotherm by 261.0% during the 4th quarter. Advisor Group Holdings Inc. now owns 7,968 shares of the company’s stock worth $166,000 after acquiring an additional 5,761 shares in the last quarter. Hedge funds and other institutional investors own 69.67% of the company’s stock.

Vapotherm Company Profile (Get Rating)

Vapotherm, Inc, a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface.

Further Reading

Insider Buying and Selling by Quarter for Vapotherm (NYSE:VAPO)

Receive News & Ratings for Vapotherm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vapotherm and related companies with MarketBeat.com's FREE daily email newsletter.